Brief: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

Moleculin Biotech

25/03/2024 13:35

March 25 (Reuters) - Moleculin Biotech Inc  MBRX.O :
    * MOLECULIN ANNOUNCES POSITIVE INTERIM DATA IN ANNAMYCIN
MB-106
PHASE 1B/2 AML TRIAL
    * MOLECULIN BIOTECH INC - ANNAMYCIN IN COMBINATION WITH
CYTARABINE
(ANNARAC) ACHIEVES CRC RATE OF 60% (50% CR) IN 2(ND) LINE AML
SUBJECTS
    * MOLECULIN BIOTECH INC - ALL 82 ANNAMYCIN SUBJECTS (IN
MULTIPLE
STUDIES) CONTINUE TO SHOW NO SIGNS OF CARDIOTOXICITY DURING
STUDY

Source text for Eikon:  ID:nPn7Vlk5Ka 
Further company coverage:  MBRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))